Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.65 |
| ▸ | TAS2R14 | Q9NYV8 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048052 | 0.92 | CNR2 (0.75) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL5050520 | 0.91 | TAS2R14 (0.56) | CNR2TAS2R14ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5049446 | 0.89 | CNR2 (0.57) | CNR2ALDH1A1 | |
| SCHEMBL5050411 | 0.89 | TAS2R14 (0.58) | CNR2TAS2R14ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4948807 | 0.89 | PTGER2 (0.56) | CNR2CA12CA1CA2CA4 | |
| SCHEMBL5725098 | 0.88 | ALDH1A1 (0.54) | CNR2ALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL5047940 | 0.88 | MAPT (0.64) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4947264 | 0.87 | ALDH1A1 (0.55) | CNR2ALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL5043556 | 0.86 | CNR2 (0.53) | CNR2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5725083 | 0.86 | ALDH1A1 (0.54) | CNR2ALDH1A1HPGDHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | claimed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| CN-1566096-A | Prostaglandin agonists and their use to treat bonedisorders | PFIZER (US) | 2005-01-19 | — | — | CN | claimed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | claimed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | claimed |
| CN-100439366-C | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| CN-1894245-A | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1859903-A | Use of EP2 selective receptor agonists in medical treatment | PFIZER PROD INC (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | PFIZER INC | 2005-03-24 | — | — | US | disclosed |
| CN-1566096-A | Prostaglandin agonists and their use to treat bonedisorders | PFIZER (US) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004078169-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | VDR, CYP24A1, CYP2R1 | CNR2 15/4885TAS2R14 2572/4885ALDH1A1 958/4885 |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | CNR2 765/4885TAS2R14 3722/4885ALDH1A1 532/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | CNR2 373/4885TAS2R14 4081/4885ALDH1A1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.